Unicycive Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Unicycive’s 10-K details a manufacturing-related FDA delay for oxylanthanum carbonate, a resubmitted NDA with a June 29, 2026 PDUFA, strengthened cash via ATM offerings, and new shareholder litigation.
NASDAQ
Unicycive Therapeutics files its 10-K, detailing its financial results for 2024 and providing updates on its key drug development programs, including Oxylanthanum Carbonate (OLC) and UNI-494.
NASDAQ
10-K: Unicycive Therapeutics Reports 2023 Annual Results, Highlights Progress in Kidney Disease Therapies
Unicycive Therapeutics' 2023 annual report details financial losses alongside advancements in clinical trials for their kidney disease treatments, Oxylanthanum Carbonate and UNI 494.